"As your company antes up at biotech's high stakes table, which is the better exit bet? VC's and bankers may be calling for a traditional IPO. But could the smarter bet be an M&A deal or alternative financing. What are the advantages and disadvantages of each? Is it possible to pursue multiple tracks? And if you do, how should you manage them? This panel will examine exit strategies in today's market, the pros and cons of each and a discussion of alternative strategies for achieving liquidity."

Objective1: Compare and contrast the value of IPO, M&A and other exits in today's market.

Objective2: Discuss the value of a multiple track exit and how to manage the various tracks.

Objective3: Examine the risks involved in a multiple track exit.